The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers

[1]  Hushan Yang,et al.  Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer , 2021, npj Breast Cancer.

[2]  J. Balko,et al.  Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features. , 2021 .

[3]  Howard H. Yang,et al.  CBFB cooperates with p53 to maintain TAp73 expression and suppress breast cancer , 2021, PLoS genetics.

[4]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[5]  Chun-Yu Liu,et al.  Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses , 2021, BMC Cancer.

[6]  X. Castells,et al.  Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative , 2021, British Journal of Cancer.

[7]  Zhongmin Liu,et al.  AHNAK2 Promotes Migration, Invasion, and Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Cells via the TGF-β/Smad3 Pathway , 2020, OncoTargets and therapy.

[8]  Chun-Yu Liu,et al.  Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses , 2020, BMC cancer.

[9]  Yulei N. Wang,et al.  Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA , 2020, Thoracic cancer.

[10]  Brian D. Bennett,et al.  Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3. , 2020, Nucleic acids research.

[11]  Hsi-Yuan Huang,et al.  Pathway mutations in breast cancer using whole-exome sequencing. , 2020, Oncology research.

[12]  R. Karchin,et al.  Integrated Informatics Analysis of Cancer-Related Variants , 2020, JCO clinical cancer informatics.

[13]  Hui Zhang,et al.  MicroRNA-299-5p inhibits cell metastasis in breast cancer by directly targeting serine/threonine kinase 39 , 2020, Oncology reports.

[14]  E. Lander,et al.  Identification of cancer driver genes based on nucleotide context , 2019, Nature Genetics.

[15]  Anas M. Saad,et al.  Causes of death after breast cancer diagnosis: A US population‐based analysis , 2019, Cancer.

[16]  J. Heymach,et al.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.

[17]  R. Karchin,et al.  CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. , 2019, Cell systems.

[18]  Hailing Lu,et al.  Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets. , 2019, Vaccine.

[19]  Howard H. Yang,et al.  The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription , 2019, Nature Communications.

[20]  H. Carter,et al.  GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors , 2019, bioRxiv.

[21]  H. Harrison,et al.  The RUNX Transcriptional Coregulator, CBFβ, Suppresses Migration of ER+ Breast Cancer Cells by Repressing ERα-Mediated Expression of the Migratory Factor TFF1 , 2019, Molecular Cancer Research.

[22]  Helen E. Parkinson,et al.  The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 , 2018, Nucleic Acids Res..

[23]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[24]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[25]  Xiu-zhi Guo,et al.  Methylation of NBPF1 as a novel marker for the detection of plasma cell-free DNA of breast cancer patients. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[26]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[27]  L. Pusztai,et al.  An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes , 2018, British Journal of Cancer.

[28]  Qi Zhao,et al.  STK39 blockage by RNA interference inhibits the proliferation and induces the apoptosis of renal cell carcinoma , 2018, OncoTargets and therapy.

[29]  L. Saal,et al.  Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Accelerating , 2018, Eureka!.

[32]  Tom R. Gaunt,et al.  CScape: a tool for predicting oncogenic single-point mutations in the cancer genome , 2017, Scientific Reports.

[33]  Tom R. Gaunt,et al.  CScape: a tool for predicting oncogenic single-point mutations in the cancer genome , 2017, Scientific Reports.

[34]  Patrick McGillivray,et al.  Using ALoFT to determine the impact of putative loss-of-function variants in protein-coding genes , 2017, Nature Communications.

[35]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[36]  Yun Cao,et al.  STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation , 2017, Oncology letters.

[37]  J. Michael Cherry,et al.  Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource , 2017, bioRxiv.

[38]  Piero Fariselli,et al.  PhD-SNPg: a webserver and lightweight tool for scoring single nucleotide variants , 2017, Nucleic Acids Res..

[39]  Valeria Vitelli,et al.  Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome , 2017, Breast Cancer Research.

[40]  J. Michael Cherry,et al.  Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource , 2017, bioRxiv.

[41]  Trevor Hastie,et al.  REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.

[42]  Z. Li,et al.  Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells , 2016, Oncotarget.

[43]  Xiaohua Chen,et al.  A novel subtype classification and risk of breast cancer by histone modification profiling , 2016, Breast Cancer Research and Treatment.

[44]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[45]  E. Osinaga,et al.  MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. , 2016, International journal of oncology.

[46]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[47]  Yun Qin,et al.  Tumor-Suppressor Gene NBPF1 Inhibits Invasion and PI3K/mTOR Signaling in Cervical Cancer Cells , 2016, Oncology research.

[48]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[49]  David L. Masica,et al.  Assessing the Pathogenicity of Insertion and Deletion Variants with the Variant Effect Scoring Tool (VEST‐Indel) , 2015, Human mutation.

[50]  H. Gogas,et al.  Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study , 2015, PloS one.

[51]  O. Hofmann,et al.  VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research , 2016, Nucleic acids research.

[52]  R. Gibbs,et al.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. , 2015, Human molecular genetics.

[53]  Xiaohui Xie,et al.  DANN: a deep learning approach for annotating the pathogenicity of genetic variants , 2015, Bioinform..

[54]  Kevin Y. Yip,et al.  FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer , 2014, Genome Biology.

[55]  D. Rea,et al.  Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Tom R. Gaunt,et al.  Ranking non-synonymous single nucleotide polymorphisms based on disease concepts , 2014, Human Genomics.

[57]  Richard Leslie,et al.  GRASP: analysis of genotype-phenotype results from 1390 genome-wide association studies and corresponding open access database , 2014, Bioinform..

[58]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[59]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[60]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[61]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[62]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[63]  Bal Sanghera,et al.  Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? , 2012, Insights into Imaging.

[64]  V. Gouyer,et al.  MUC5B Leads to Aggressive Behavior of Breast Cancer MCF7 Cells , 2012, PloS one.

[65]  Gabor T. Marth,et al.  Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.

[66]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[67]  M. Shackleton,et al.  Physiological Levels of Pik3ca H1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors , 2012, PloS one.

[68]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[69]  L. Pusztai,et al.  Gene expression profi ling in breast cancer: classifi cation, prognostication, and prediction , 2011 .

[70]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[71]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[72]  Elizabeth Reed,et al.  Multicenter Breast Cancer Collaborative Registry , 2011, Cancer informatics.

[73]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[74]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[75]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[76]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[77]  Paul Ellis,et al.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.

[78]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[79]  Jorge S Reis-Filho,et al.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.

[80]  Ken Chen,et al.  VarScan: variant detection in massively parallel sequencing of individual and pooled samples , 2009, Bioinform..

[81]  Z. Werb,et al.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.

[82]  D. Hayes.  Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer , 2007 .

[83]  Marie-Liesse Asselin-Labat,et al.  Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.

[84]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  Alan Ashworth,et al.  Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance , 2006, Breast Cancer Research and Treatment.

[86]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[87]  R. Weigel,et al.  GATA-3 expression as a predictor of hormone response in breast cancer. , 2005, Journal of the American College of Surgeons.

[88]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  E. Osinaga,et al.  Detection of bone marrow‐disseminated breast cancer cells using an RT‐PCR assay of MUC5B mRNA , 2003, International journal of cancer.

[90]  A. Kassens.  Targets , 2019, Intemperate Spirits.

[91]  C. Velde,et al.  Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. , 2018, Cancer treatment reviews.

[92]  N. Socci,et al.  Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.

[93]  Erwin G. Van Meir,et al.  Adhesion GPCRs in Tumorigenesis. , 2016, Handbook of experimental pharmacology.

[94]  Sara A. Grimm,et al.  GATA3 in Breast Cancer: Tumor Suppressor or Oncogene? , 2015, Gene expression.

[95]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[96]  Vanessa Andries.  Functional analysis of the NBPF1 gene in cancer , 2012 .

[97]  S. Yona,et al.  Adhesion-GPCRs structure to function , 2010 .

[98]  S. Yona,et al.  Adhesion-GPCRs: structure to function. Preface. , 2010, Advances in experimental medicine and biology.

[99]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[100]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..